Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29587848 | 1.00 | LMNA (0.40) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL29589098 | 1.00 | LMNA (0.40) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL1509092 | 0.97 | LMNA (0.35) | LMNACA2CA1MMP1MMP2 | |
| SCHEMBL396425 | 0.76 | LMNA (0.50) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL396442 | 0.76 | LMNA (0.50) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL392843 | 0.76 | LMNA (0.50) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL6287445 | 0.76 | LMNA (0.50) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL345870 | 0.76 | LMNA (0.50) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL394930 | 0.76 | LMNA (0.50) | LMNACA2THRBCA1MMP1 | |
| SCHEMBL1707474 | 0.73 | LMNA (0.61) | LMNACA2THRBCA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152554-A1 | ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING AVOCADO/SOYBEAN UNSAPONIFIABLES AND LIPOIC ACID AND METHODS OF ADMINISTRATION | NUTRAMAX LABORATORIES, INC. (US) | 2025-05-15 | — | — | US | claimed |
| US-12226397-B2 | Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration | NUTRAMAX LABORATORIES, INC. (US) | 2025-02-18 | — | — | US | claimed |
| CN-117620523-A | Photo-curing solder paste and preparation method thereof | 苏州柯仕达电子材料有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-114561072-B | Preparation method of inorganic filler doped modified FEP composite dielectric film | 浙江工业大学 | 2023-07-25 | — | — | CN | claimed |
| CN-116338068-A | Risk grading method for content of PFOS-containing solid waste toxic substances | 沈阳沈化院测试技术有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20250152554-A1 | ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING AVOCADO/SOYBEAN UNSAPONIFIABLES AND LIPOIC ACID AND METHODS OF ADMINISTRATION | NUTRAMAX LABORATORIES, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| US-12226397-B2 | Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration | NUTRAMAX LABORATORIES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-117620523-A | Photo-curing solder paste and preparation method thereof | 苏州柯仕达电子材料有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117229592-A | Poly (perfluoroethylene-propylene) composite material and preparation method and application thereof | 中国石油大学(北京) | 2023-12-15 | — | — | CN | disclosed |
| CN-114561072-B | Preparation method of inorganic filler doped modified FEP composite dielectric film | 浙江工业大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-116338068-A | Risk grading method for content of PFOS-containing solid waste toxic substances | 沈阳沈化院测试技术有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2012162063-A1 | ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING AVOCADO/SOYBEAN UNSAPONIFIABLES AND LIPOIC ACID AND METHODS OF ADMINISTRATION | NUTRAMAX LABORATORIES, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| EP-0456093-A2 | Biguanide derivatives and biocidal compositions containing them | H.B. FULLER LICENSING & FINANCING, INC. (US) | 1991-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226397-B2 | Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration | ALOX15B, ALOX15, ALOX12 | LMNA 642/4885CA2 1440/4885THRB 3515/4885 |
| US-20250152554-A1 | ORALLY ADMINISTRABLE COMPOSITIONS COMPRISING AVOCADO/SOYBEAN UNSAPONIFIABLES AND LIPOIC ACID AND METHODS OF ADMINISTRATION | ALOX15B, ALOX15, ALOX12 | LMNA 642/4885CA2 1440/4885THRB 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.